Skip to main content
. 2020 Mar 16;27(4):671–680.e2. doi: 10.1016/j.chom.2020.03.002

Table 5.

Dominant SARS-CoV T Cell Epitopes

SARS
 SARS-CoV-2
Sequence RF Score HLA Restrictiona Sequence Protein Mapped Start–End Identity (%)
VRGWVFGSTMNNKSQSVI 0.15 DRB1∗04:01 IRGWIFGTTLDSKTQSLL S 101–118 50
CTFEYISDAFSLD 0.21 DRB1∗04:01 CTFEYVSQPFLMD S 166–178 62
DAFSLDVSEKSGN 0.62 DRB1∗04:01 QPFLMDLEGKQGN S 173–185 38
TNFRAILTAFSPAQDIW 0.32 DRB1∗04:01 TRFQTLLALHRSYLTPGDSSSGW S 236–258 17
KSFEIDKGIYQTSNFRVV 0.40 DRB1∗04:01, DRB1∗07:01 KSFTVEKGIYQTSNFRVQ S 304–321 78
STFFSTFKCYGVSATKL 0.50 DRB1∗07:01, DR8 SASFSTFKCYGVSPTKL S 371–387 82
KLPDDFMGCV 0.55 A∗02:01 KLPDDFTGCV S 424–433 90
NIDATSTGNYNYKYRYLR 0.29 Class II NLDSKVGGNYNYLYRLFR S 440–457 56
YLRHGKLRPFERDISNVP 0.16 DRB1∗04:01 YLYRLFRKSNLKPFERDI S 451–468 58
RPFERDISNVPFS 0.36 DRB1∗04:01 KPFERDISTEIYQ S 462–474 54
KSIVAYTMSLGADSSIAY 0.15 DRB1∗04:01, DRB1∗07:01 QSIIAYTMSLGAENSVAY S 690–707 72
SIVAYTMSL 0.29 A∗02:01 SIIAYTMSL S 691–699 89
TECANLLLQYGSFCTQL 0.50 DR8 TECSNLLLQYGSFCTQL S 747–763 94
VKQMYKTPTLKYFGGFNF 0.20 DRB1∗04:01 VKQIYKTPPIKDFGGFNF S 785–802 78
ESLTTTSTALGKLQDVV 0.42 DRB1∗04:01 DSLSSTASALGKLQDVV S 936–952 71
ALNTLVKQL 0.29 A∗02:01 ALNTLVKQL S 958–966 100
VLNDILSRL 0.29 A∗02:01 VLNDILSRL S 976–984 100
LITGRLQSL 0.42 A∗02:01 LITGRLQSL S 996–1004 100
QLIRAAEIRASANLAATK 0.20 DRB1∗04:01 QLIRAAEIRASANLAATK S 1011–1028 100
SWFITQRNFFSPQII 0.60 DRB1∗04:01 HWFVTQRNFYEPQII S 1101–1115 73
RLNEVAKNL 0.42 A∗02:01 RLNEVAKNL S 1185–1193 100
NLNESLIDL 0.29 A∗02:01 NLNESLIDL S 1192–1200 100
FIAGLIAIV 0.80 A∗02:01 FIAGLIAIV S 1220–1228 100
RFFTLGSITAQPVKI 0.18 B∗58:01 RIFTIGTVTLKQGEI Orf 3a 6–20 40
SITAQPVKI 0.29 B∗58:01 TVTLKQGEI Orf 3a 12–20 22
TLACFVLAAV 0.59 A∗02:01 TLACFVLAAV M 61–70 100
GLMWLSYFV 0.59 A∗02:01 GLMWLSYFI M 89–97 89
HLRMAGHSL 0.40 Class I HLRIAGHHL M 148–156 78
ALNTPKDHI 0.29 A∗02:01 ALNTPKDHI N 138–146 100
LQLPQGTTL 0.29 A∗02:01 LQLPQGTTL N 159–167 100
GETALALLLL 0.38 B∗40:01 GDAALALLLL N 215–224 80
LALLLLDRL 0.29 A∗02:01 LALLLLDRL N 219–227 100
LLLDRLNQL 0.42 A∗02:01 LLLDRLNQL N 222–230 100
RLNQLESKV 0.42 A∗02:01 RLNQLESKM N 226–234 89
TKQYNVTQAF 0.29 Class I TKAYNVTQAF N 265–274 90
GMSRIGMEV 0.42 A∗02:01 GMSRIGMEV N 316–324 100
MEVTPSGTWL 0.42 B∗40:01 MEVTPSGTWL N 322–331 100
QFKDNVILL 0.50 A∗24:02 NFKDQVILL N 345–353 78
CLDAGINYV 0.42 A∗02:01 CLEASFNYL Orf 1ab 2139–2147 56
WLMWFIISI 0.42 A∗02:01 WLMWLIINL Orf 1ab 2292–2300 67
ILLLDQVLV 0.42 A∗02:01 ILLLDQALV Orf 1ab 2498–2506 89
LLCVLAALV 0.42 A∗02:01 SACVLAAEC Orf 1ab 2840–2848 56
ALSGVFCGV 0.42 A∗02:01 SLPGVFCGV Orf 1ab 2942–2950 78
TLMNVITLV 0.42 A∗02:01 TLMNVLTLV Orf 1ab 3639–3647 89
SMWALVISV 0.42 A∗02:01 SMWALIISV Orf 1ab 3661-3669 89

S, surface glycoprotein; M, membrane protein; N, nucleocapsid phosphoprotein.

a

Restrictions defined only in HLA-transgenic mice are indicated by the italicized font.